Sort   by:  
 Page size 
UnknownDiscovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.
A novel peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist 5c was developed with an EC50 of 8 nM for PPARα, 5 nM for PPARδ, and >300-fold selectivity against PPARγ (EC50 = 2939 nM), respectively. Further ADME and pharmacokinetic studies indicated 5c
S-EPMC6627728 | biostudies-literature
UnknownDesign, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy.
Angiokinases, such as vascular endothelial-, fibroblast- and platelet-derived growth factor receptors (VEGFRs, FGFRs and PDGFRs) play crucial roles in tumor angiogenesis. Anti-angiogenesis therapy using multi-angiokinase inhibitor has achieved great success in recent years. In this study, we present...
S-EPMC7488503 | biostudies-literature
UnknownChemical Source Profiles and Toxicity Assessment of Urban Fugitive Dust PM2.5 in Guanzhong Plain, China.
Urban fugitive dust is a significant contributor to atmospheric PM2.5 and a potential risk to humans. In 2019, both road dust and construction dust were collected from four cities, including Xi'an, Xianyang, Baoji, and Tongchuan, in Guanzhong Plain, China. Elements, water-soluble ions, an...
S-EPMC10458601 | biostudies-literature
UnknownNanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Paclitaxel (PTX) has shown pleiotropic immunologic effects on the tumor microenvironment, and nanomicelle has emerged as a promising strategy for PTX delivery. However, the detailed mechanisms remain to be fully elucidated. Meanwhile, immunogenic cell death (ICD) is an effective approach to activate...
S-EPMC7381738 | biostudies-literature
UnknownSafety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Not available
S-EPMC7561304 | biostudies-literature
Sort   by:  
 Page size